Prism Medico and Pharmacy reported unaudited standalone results for the quarter ended September 30, 2026. Quarterly net profit was Rs.22.65 lakhs, versus a loss a year earlier.
Prism Medico and Pharmacy will hold a board meeting on November 5, 2026 to consider unaudited standalone half-yearly financial results for the period ended September 2026. The trading window closes from October 1 until November 7, 2026.
Prism Medico and Pharmacy intimated BSE and MSEI that its corporate website is updated and functional per Regulation 46. This is a routine compliance undertaking with no financial impact.
Prism Medico and Pharmacy Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31. This is a routine filing.
Prism Medico and Pharmacy Limited has informed that no interest, dividend, or principal is payable on non-convertible securities for the quarter ending December 31, 2026.
Prism Medico and Pharmacy Limited re-appointed Davender Singh as a Non-Executive Non-Independent Director. The company also updated its statutory and secretarial auditor appointments.
Prism Medico and Pharmacy held its 24th Annual General Meeting on September 19, 2026, to transact ordinary and special business, including various investment approvals.
Prism Medico and Pharmacy Limited has filed its Annual Report for the financial year 2025-2026 in accordance with Regulation 34 of SEBI LODR Regulations.
Prism Medico and Pharmacy Limited has scheduled its 24th Annual General Meeting for September 19, 2026, through video conferencing to transact ordinary and special business.
Prism Medico and Pharmacy's board approved the Director's Report and the 24th AGM notice for September 19, 2026. It also recommended auditor appointments and preferential issue object variation.
Prism Medico and Pharmacy Limited has scheduled a board meeting for August 12, 2026, to consider its standalone unaudited financial results for the quarter ended June 2026.
Prism Medico and Pharmacy approved its FY26 audited financial results showing annual revenue of ₹2.44 Crore. The board confirmed an unmodified audit opinion for the period.
Prism Medico and Pharmacy scheduled a board meeting on May 28, 2026. Directors will consider audited standalone financial results for the quarter and year ended March 2026.